Abstract
Hypoxic tissue exists in most of the solid tumors and hypoxia is a common character of these tumors. The existence of hy-poxic tissue in the tumor decreases the efficacy of radiotherapy and chemotherapy. Radiolabeled hypoxia markers have been developed to measure the hypoxic tissue together with non-invasive imaging techniques such as PET, SPECT, and PET/CT. This offers a conven-ient approach to delineate the tumor providing useful information for diagnosing cancer and guiding the treatment plan. Bioreducible or-ganic compounds have been developed as the hypoxia markers to probe tissue hypoxia noninvasively because they can be reduced and metabolized under hypoxic conditions; form adducts with cell components, and thus be trapped in the hypoxic tissue. These compounds include nitroimidazoles and other redox-sensitive compounds such as BnAO and ATSM. Different radionuclides have been used to label these compounds such as technetium-99m, iodine-123, fluorine-18, copper-64, etc. In addition, to detect h ypoxia with endogenous hy-poxia markers such as carbonic anhydrase IX (CA IX) and hypoxia-inducible factor-1 (HIF-1), some radiolabeled tracers have also been developed. This article is an overview of the progress in this area in the past decade including the development of radiolabeled com-pounds for hypoxia detection and problems associated with the hypoxia marker development.
Keywords: Radionuclide, tumor, hypoxia imaging agent, nitroimidazole, redox-sensitive compounds, radiotherapy, chemotherapy, technetium-99m, iodine-123, fluorine-18
Current Pharmaceutical Design
Title: Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Volume: 18 Issue: 8
Author(s): Zejun Li and Taiwei Chu
Affiliation:
Keywords: Radionuclide, tumor, hypoxia imaging agent, nitroimidazole, redox-sensitive compounds, radiotherapy, chemotherapy, technetium-99m, iodine-123, fluorine-18
Abstract: Hypoxic tissue exists in most of the solid tumors and hypoxia is a common character of these tumors. The existence of hy-poxic tissue in the tumor decreases the efficacy of radiotherapy and chemotherapy. Radiolabeled hypoxia markers have been developed to measure the hypoxic tissue together with non-invasive imaging techniques such as PET, SPECT, and PET/CT. This offers a conven-ient approach to delineate the tumor providing useful information for diagnosing cancer and guiding the treatment plan. Bioreducible or-ganic compounds have been developed as the hypoxia markers to probe tissue hypoxia noninvasively because they can be reduced and metabolized under hypoxic conditions; form adducts with cell components, and thus be trapped in the hypoxic tissue. These compounds include nitroimidazoles and other redox-sensitive compounds such as BnAO and ATSM. Different radionuclides have been used to label these compounds such as technetium-99m, iodine-123, fluorine-18, copper-64, etc. In addition, to detect h ypoxia with endogenous hy-poxia markers such as carbonic anhydrase IX (CA IX) and hypoxia-inducible factor-1 (HIF-1), some radiolabeled tracers have also been developed. This article is an overview of the progress in this area in the past decade including the development of radiolabeled com-pounds for hypoxia detection and problems associated with the hypoxia marker development.
Export Options
About this article
Cite this article as:
Li Zejun and Chu Taiwei, Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315849
DOI https://dx.doi.org/10.2174/138161212799315849 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?
Current Pharmaceutical Design Management of Fallopian Tube Cancer
Reviews on Recent Clinical Trials Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design Therapeutic Strategies for Papillary Microcarcinoma of the Thyroid
Current Cancer Therapy Reviews Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α
Current Cancer Therapy Reviews miRNAs in the Biology of Cancers and Viral Infections
Current Medicinal Chemistry HIV-1 Vpr: Enhancing Sensitivity of Tumors to Apoptosis
Current Drug Delivery Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Investigation of the Antiproliferative Action of the Quinoline Alkaloids Kokusaginine and Skimmianine on Human Cell Lines
Current Signal Transduction Therapy Cytotoxic and Chemopreventive Effects of Gemin D Against Different Mutagens Using In Vitro and In Vivo Assays
Anti-Cancer Agents in Medicinal Chemistry <i>In Silico</i> Docking of Anti Cancerous Drugs with β-Cyclodextrin polymer as a Prominent Approach to Improve the Bioavailability
Anti-Cancer Agents in Medicinal Chemistry Effect of Monoamine Oxidase Inhibition on Rewarding Effects of Nicotine in Rodents
Current Drug Abuse Reviews Proteins Expressed Differently Between Glucose and Glycerol for Schizochytrium limacinum SR21
Current Biotechnology The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews